A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Stopped early · Phase 2

Conditions studied: Multiple Myeloma

In brief

This open-label study will assess anti-tumor activity and safety of belinostat in combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or relapsed from at least one prior bortezomib-containing regimen. Subjects will be administered both PXD101 and bortezomib on the same days: i.e. days 1, 4, 8, and 11 of a 3-week cycle, for up to 8 cycles.

Key facts

Study ID

NCT00431340

Run by

Valerio Therapeutics

People needed

4

Starts

2007-03-01

Expected to finish

2007-06-01

Last updated by the study team

2015-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of multiple myeloma.
• Status of refractory to or relapsed from at least one prior bortezomib-containing regimen.
• Progressive disease.
• Age >= 18 years.
• Karnofsky performance status >= 60%
• Acceptable liver function:
• Bilirubin =< 1.5 x ULN (upper limit of normal)
• Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN
• Acceptable hematologic status:
• Absolute Neutrophil Count (ANC) >= 1.5 x 109/L
• Platelet count >= 100 x 109/L
• Hemoglobin >= 9 g/dL
• Coagulation status PT-INR/PTT =< 1.5 x ULN or in the therapeutic range if on anticoagulation therapy. (PT-INR/PTT= prothrombin - international normalized ratio / prothrombin time)
• Serum potassium within normal range.
• Estimated life expectancy greater than 3 months.
• Signed, written IRB (institutional Review Board)-approved informed consent.

You may not qualify if…

• Non-secretory multiple myeloma or symptomatic amyloidosis.
• Hypersensitivity to bortezomib, boron, or mannitol.
• Less than 4 weeks since prior chemotherapy, radiotherapy, endocrine therapy, or immunotherapy, except if disease is rapidly progressing.
• Less than 4 weeks since prior use of other investigational agents.
• Serious concomitant systemic disorders (e.g. active infection).
• Significant cardiovascular disease.
• Marked baseline prolongation of QT/QTc (corrected QT interval)interval.
• Central nervous system disorders requiring neuroleptics / anti-convulsants.
• Peripheral sensory neuropathy of ≥ Grade 2
• Renal insufficiency defined as a creatinine clearance of < 30 ml/min.
• Non-willingness to use effective contraceptive methods for patients of child-bearing age / potential.
• Pregnant or breast-feeding women.
• Known HIV positivity.
• Prior treatment with belinostat (PXD101), or any other HDAC (histone deacetylase) inhibitor.
• Altered mental status which precludes an understanding of the Informed Consent Document.

Where it is running

• Oncotherapeutics — West Hollywood, California, United States
• Center for cancer and blood disorders — Bethesda, Maryland, United States
• Baylor University Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.